Jonathan Pachter

Company: Verastem
Job title: Chief Scientific Officer
Seminars:
The RAF/MEK Clamp VS-6766 for Treatment of KRAS & BRAF Mutant NSCLC 9:30 am
Exploring anti-tumor activity across multiple MAPK pathway alterations Ongoing VS-6766 combinations with FAK, KRAS G12C or mTOR inhibitors Revealing new combinations with EGFR inhibitorsRead more
day: Day Two